- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (68)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (26)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (230)
- Breast Cancer (720)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (156)
- Colon Cancer (164)
- Colorectal Cancer (112)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (8)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (8)
- Kidney Cancer (126)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (286)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (100)
- Ovarian Cancer (172)
- Pancreatic Cancer (164)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (236)
- Skin Cancer (296)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (96)
- Tonsil Cancer (30)
- Uterine Cancer (80)
- Vaginal Cancer (16)
- Vulvar Cancer (20)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (632)
- Complementary Integrative Medicine (24)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (230)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (124)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (118)
- Molecular Diagnostics (8)
- Pain Management (62)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (908)
- Research (396)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (606)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (402)
- Survivorship (322)
- Symptoms (184)
- Treatment (1784)
Discovering a more aggressive form of endometrial cancer
BY Ron Gilmore
2 minute read | Published September 08, 2014
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on September 08, 2014

Parents of twins often tell them apart through subtle differences such as facial expression, moles, voice tone and gait. Similarly, physicians treating women with endometrial cancer, or cancer of the uterine lining, must be able to distinguish between different versions of this disease that on the surface may appear the same.
“The most common form of endometrial cancer, known as endometrioid endometrial carcinoma, or EEC, is categorized into subtypes that help determine risk of recurrence and guide treatment,” said Wei Zhang, Ph.D., professor of Pathology at MD Anderson.
Seventy to 80% of patients have Type I, which can be diagnosed early and generally has a good outcome with treatment.
However, Zhang identified a cluster of patients within Type I who appear to have a more virulent form of the disease previously not recognized. To differentiate between the two groups, he named the patients with less aggressive Type I cancer “Cluster I,” and the patients with more aggressive Type I cancer “Cluster II.”
On the surface, the Cluster I and Cluster II patients had the same characteristics — they were mostly young and obese, which is typical of Type 1 endometrial cancer. Mortality rates from this cancer have nearly tripled in the last 25 years and are thought to be related to obesity.
But when Zhang and his team began analyzing Cluster II patients’ tumors, they found distinctive genetic mutations in 87% of the patients. The mutations occurred in the CTNNB1 gene, which is necessary for the creation and maintenance of tissue-producing epithelial cells. Within CTNNB1, genetic sequences known as exon 3 created a “hotspot,” a cellular cauldron of biological blunders. This resulted in the normally passive Type 1 becoming deadly for some patients.
“The identification of this second cluster of patients with endometrial cancer helps to refute long-standing teachings that young, obese patients universally have endometrial cancers that are estrogen-driven and thus have a good prognosis,” said Russell Broaddus, M.D., Ph.D., professor of Pathology at MD Anderson. “Endometrial cancer in this patient population is much more complex than we were previously led to believe. ”
Zhang believes that Cluster II patients, if identified early, can be treated more aggressively for a better outcome.
The study’s findings were published in an article appearing in this month’s issue of the Journal of the National Cancer Institute.